Literature DB >> 15236469

Activin mRNA induced during amygdala kindling shows a spatiotemporal progression that tracks the spread of seizures.

Jane A Foster1, Michael J Puchowicz, Dan C McIntyre, Miles Herkenham.   

Abstract

The progressive development of seizures in rats by amygdala kindling, which models temporal lobe epilepsy, allows the study of molecular regulators of enduring synaptic changes. Neurotrophins play important roles in synaptic plasticity and neuroprotection. Activin, a member of the transforming growth factor-beta superfamily of growth and differentiation factors, has recently been added to the list of candidate synaptic regulators. We mapped the induction of activin betaA mRNA in amygdala and cortex at several stages of seizure development. Strong induction, measured 2 hours after the first stage 2 (partial) seizure, appeared in neurons of the ipsilateral amygdala (confined to the lateral, basal, and posterior cortical nuclei) and insular, piriform, orbital, and infralimbic cortices. Activin betaA mRNA induction, after the first stage 5 (generalized) seizure, had spread to the contralateral amygdala (same nuclear distribution) and cortex, and the induced labeling covered much of the convexity of neocortex as well as piriform, perirhinal, and entorhinal cortices in a nearly bilaterally symmetrical pattern. This pattern had filled in by the sixth stage 5 seizure. Induced labeling in cortical neurons was confined mainly to layer II. A similar temporal and spatial pattern of increased mRNA expression of brain-derived neurotrophic factor (BDNF) was found in the amygdala and cortex. Activin betaA and BDNF expression patterns were similar at 1, 2, and 6 hours after the last seizure, subsiding at 24 hours; in contrast, c-fos mRNA induction appeared only at 1 hour throughout cortex and then subsided. In double-label studies, activin betaA mRNA-positive neurons were also BDNF mRNA positive, and they did not colocalize with GAD67 mRNA (a marker of gamma-aminobutyric acidergic neurons). The data suggest that activin and BDNF transcriptional activities accurately mark excitatory neurons participating in seizure-induced synaptic alterations and may contribute to the enduring changes that underlie the kindled state. Published 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15236469     DOI: 10.1002/cne.20197

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  6 in total

1.  Stage-specific modulation of neprilysin and aminopeptidase N in the limbic system during kindling progression.

Authors:  Patricia de Gortari; Miguel Angel Vargas; Adrián Martínez; Arlene I García-Vázquez; Rosa María Uribe; Lucía Chávez-Gutiérrez; Víctor Magdaleno; Guy Boileau; Jean-Louis Charlí; Patricia Joseph-Bravo
Journal:  J Mol Neurosci       Date:  2007-04-17       Impact factor: 3.444

2.  Impact of treadmill running and sex on hippocampal neurogenesis in the mouse model of amyotrophic lateral sclerosis.

Authors:  Xiaoxing Ma; Mazen J Hamadeh; Brain R Christie; Jane A Foster; Mark A Tarnopolsky
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

Review 3.  The piriform cortex and human focal epilepsy.

Authors:  David N Vaughan; Graeme D Jackson
Journal:  Front Neurol       Date:  2014-12-08       Impact factor: 4.003

Review 4.  Hyperexcitability: From Normal Fear to Pathological Anxiety and Trauma.

Authors:  Jeffrey B Rosen; Jay Schulkin
Journal:  Front Syst Neurosci       Date:  2022-08-04

5.  Activin signaling as an emerging target for therapeutic interventions.

Authors:  Kunihiro Tsuchida; Masashi Nakatani; Keisuke Hitachi; Akiyoshi Uezumi; Yoshihide Sunada; Hiroshi Ageta; Kaoru Inokuchi
Journal:  Cell Commun Signal       Date:  2009-06-18       Impact factor: 5.712

6.  Activin A is essential for neurogenesis following neurodegeneration.

Authors:  Andrea Abdipranoto-Cowley; Jin Sung Park; David Croucher; James Daniel; Susan Henshall; Sally Galbraith; Kyle Mervin; Bryce Vissel
Journal:  Stem Cells       Date:  2009-06       Impact factor: 6.277

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.